Studies of Autistic Patients: Gene Networks and Clinical Subtypes

Learn more about:
Related Clinical Trial
Doxycycline In Lymphangioleiomyomatosis (LAM) Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women Turmeric as Treatment in Epilepsy Study of the Disease Process of Lymphangioleiomyomatosis RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM The Effectiveness and Safety of Vagus Nerve Stimulation for TRE The Effectiveness and Safety of Resective Epilepsy Surgery for TRE Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) Safety of Simvastatin in LAM and TSC Studies of Autistic Patients: Gene Networks and Clinical Subtypes Topical Rapamycin to Erase Angiofibromas in TSC Rapalogues for Autism Phenotype in TSC: A Feasibility Study A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Everolimus for Cancer With TSC1 or TSC2 Mutation Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex The Cognitive Variability in NF1 and TSC Monozygotic Twins Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy – Tuberous Sclerosis Complex A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex JASPER Early Intervention for Tuberous Sclerosis Studies in Patients With Tuberous Sclerosis Complex Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex (TuScCom) Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) Tuberous Sclerosis Complex Natural History Study: Renal Manifestations Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) Study of Skin Tumors in Tuberous Sclerosis

Brief Title

Studies of Autistic Patients: Gene Networks and Clinical Subtypes

Official Title

Studies of Autistic Patients: Gene Networks and Clinical Subtypes

Brief Summary

      Background:

        -  Researchers who are studying autism spectrum disorders are interested in developing a
           collection of research samples from both children with autism and healthy individuals,
           some of whom may be related to the children with autism.

        -  The genetic condition tuberous sclerosis, which can cause the growth of benign tumors in
           the brain and other parts of the body, is also linked with autism. Researchers have been
           able to determine the specific genetic mutations involved in tuberous sclerosis, and as
           a result are interested in studying the genetic information of children who have both
           tuberous sclerosis and autism, as well as tuberous sclerosis without autism.

      Objectives:

      - To develop a collection of DNA samples from blood and skin samples taken from children with
      autism and/or tuberous sclerosis, as well as healthy volunteers.

      Eligibility:

        -  Children between 4 to 18 years of age who have autism and/or tuberous sclerosis, or are
           healthy volunteers.

        -  Some of the healthy volunteers will be siblings of children with autism.

      Design:

        -  Participants will be screened with a medical history and a physical examination, and may
           also have a genetic evaluation.

        -  Participants will provide a blood sample and a skin biopsy for further study.

        -  No treatment will be provided as part of this protocol.
    

Detailed Description

      The aim of this protocol is to provide further elucidation of the clinical phenotype of
      autism, and second to characterize a potential cellular phenotype through the re-programming
      of fibroblasts into induced pluripotent stem cells (iPS cells). The scope of autistic
      spectrum disorders (ASD) is defined by its behavioral symptoms, encompassing a group of
      conditions that includes Asperger disorder, autism and pervasive developmental disorder-not
      otherwise specified (PDD). The clinical presentation of each of these diagnostic groups
      differs slightly, but all share three common features: deficits in social reciprocity, delays
      or deficits in communication (both verbal and non-verbal) and presence of repetitive
      behaviors and fixated interests. These symptoms are most pronounced in the autism group, so
      they will serve as the subjects for this pilot investigation. Individual differences in
      behavioral symptoms, genetic abnormalities, medical comorbidities and other risk factors will
      be assessed. These approaches will be coupled with computational approaches to identify
      neural networks by analysis of gene association study data, and analysis of gene databases to
      relate the diagnostic criteria of autism by unbiased analysis of the ontology of genes
      relevant to CNS function.
    


Study Type

Observational




Condition

Autism



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

11

Start Date

March 17, 2010

Completion Date

September 24, 2013


Eligibility Criteria

        -  INCLUSION CRITERIA:

        Autism Groups:

        Meeting criteria for a diagnosis of autism, based on the Autism Diagnostic
        Interview-Revised and the Autism Diagnostic Observation Schedule, as well as clinical
        judgment.

        Health Sibling and Typically Developing Group: Within 1.5 standard deviations from the mean
        on the cognitive test performed, and lower than the cutoff scores on the Autism Diagnostic
        Interview and Autism Diagnostic Observation Schedule, and not meeting criteria for any
        psychiatric disorder on interviews or questionnaires.

        Tuberous Sclerosis Groups: Confirmed diagnosis of Tuberous Sclerosis

        EXCLUSION CRITERIA:

        Autism Groups:

        Non-idiopathic autism (e.g. previously identified genetic abnormality associated with
        autism in that individual)

        Typically Developing Group:

        History of receiving a diagnosis or services for psychiatric or significant learning issues
      

Gender

Male

Ages

4 Years - 18 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Owen M Rennert, M.D., , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01092208

Organization ID

100084

Secondary IDs

10-CH-0084


Study Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)


Study Sponsor

Owen M Rennert, M.D., Principal Investigator, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)


Verification Date

September 24, 2013